- Home
- IVVD vs AGEN Comparison
IVVD vs AGEN Comparison
Compare IVVD & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- AGEN
- Stock Information
- Founded
- IVVD 2020
- AGEN 1994
- Country
- IVVD United States
- AGEN United States
- Employees
- IVVD N/A
- AGEN N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVVD Health Care
- AGEN Health Care
- Exchange
- IVVD Nasdaq
- AGEN Nasdaq
- Market Cap
- IVVD 116.8M
- AGEN 96.2M
- IPO Year
- IVVD 2021
- AGEN 2000
- Fundamental
- Price
- IVVD $0.70
- AGEN $2.86
- Analyst Decision
- IVVD Strong Buy
- AGEN Buy
- Analyst Count
- IVVD 5
- AGEN 3
- Target Price
- IVVD $7.11
- AGEN $9.33
- AVG Volume (30 Days)
- IVVD 581.2K
- AGEN 576.6K
- Earning Date
- IVVD 11-14-2024
- AGEN 11-12-2024
- Dividend Yield
- IVVD N/A
- AGEN N/A
- EPS Growth
- IVVD N/A
- AGEN N/A
- EPS
- IVVD N/A
- AGEN N/A
- Revenue
- IVVD $11,564,000.00
- AGEN $160,427,000.00
- Revenue This Year
- IVVD N/A
- AGEN N/A
- Revenue Next Year
- IVVD $72.22
- AGEN $0.04
- P/E Ratio
- IVVD N/A
- AGEN N/A
- Revenue Growth
- IVVD N/A
- AGEN 59.00
- 52 Week Low
- IVVD $0.71
- AGEN $2.50
- 52 Week High
- IVVD $5.20
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- IVVD 33.40
- AGEN 28.17
- Support Level
- IVVD $0.72
- AGEN $2.50
- Resistance Level
- IVVD $0.81
- AGEN $2.89
- Average True Range (ATR)
- IVVD 0.07
- AGEN 0.29
- MACD
- IVVD -0.02
- AGEN -0.07
- Stochastic Oscillator
- IVVD 1.12
- AGEN 18.75
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).